We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ixico Plc | LSE:IXI | London | Ordinary Share | GB00BFXR4C20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 8.125 | 8.00 | 8.25 | 8.125 | 8.125 | 8.13 | 4,655 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
03/11/2020 07:49 | From today's update: "These contracts were included in management's expectations of performance for the coming year and contribute to the Company's strong order book. These contracts relate to trials at different stages of drug development and are with several different customers, strengthening diversification in the Company's order book." From the YE TU for 2020: "Despite this uncertainty in the clinical trials market, the Company confirms its outlook for the 2021 financial year, reflecting its strong order book of future revenues and robust balance sheet." I know EBITDA expectations for year just ended were at least £1.1m but I don't know what EBITDA expectations are for the current year. If anyone would like to jog my memory (I must have read it somewhere!?) I would be grateful. | frazboy | |
03/11/2020 07:46 | IXICO lands three new clinical trial contracts, reflecting its growing expertise in Alzheimer's disease It will carry out work on a phase I study, it has signed an expansion deal for a phase II clinical assessment and will deploy its expertise on an open-label extension phase III trial IXICO PLC - IXICO PLC (LON:IXI), the data analytics specialist focused on neuroscience, said it has landed three new contracts in the area of Alzheimer's disease. It will carry out work on a phase I study, it has signed an expansion deal for a phase II clinical assessment and will deploy its expertise on an open-label extension phase III trial. IXICO said the new business built on its expertise in the field of Alzheimer's and pointed out that it was in addition to the partnership with the Global Alzheimer's Platform announced in September. The company’s chief commercial officer, Lammert Albers, added: "Today there are 50 million people worldwide that suffer with Alzheimer's and other forms of dementias. “There are currently no means to prevent or delay onset, slow progression or meaningfully improve symptoms of Alzheimer's disease. “With more than 120 unique investigational drugs in clinical trials, IXICO is proud to support some of these potential treatments that one day may be in the hands of Alzheimer's patients worldwide." Proactiveinvestors | ariane | |
03/11/2020 07:21 | This just looks a very good investment over whatever timescale you want | donald pond | |
03/11/2020 07:12 | "Additional Alzheimer's disease contracts with new and existing large pharma clients" | michaelmouse | |
02/11/2020 15:37 | Crikey Skinny - so you are an IXI shareholder because you held PYM - you must be one of the longest standing investors here! | toffeeman | |
02/11/2020 13:58 | I can't actually remember when I bought PYM or how much I paid - suffice to say they've been decimated over time and they'd need to hundred bag from here to be worth much to me. | skinny | |
02/11/2020 13:47 | >> Skinny - thanks but FWIW = 0 in this case! | toffeeman | |
02/11/2020 11:13 | IXI the market has changed with American companies looking to buy great companies in this space. IXI fits their profile very well and with news flow will rocket well above it current value See HZD as an example...THIS IS A GAME CHANGER... | halfpenny | |
02/11/2020 09:52 | IXI charts are supporting a fantastic opportunity with Higher Highs and Lower lows. The chart says its a no brainer with Higher Highs as news flow or even a Takeover like HZD...See charts for yourself!! | halfpenny | |
02/11/2020 09:42 | Dear dear Troll Given a new set of instructions now ? Delete 'doom and gloom' posts, replace with 'sunshine and joy'. So transparent as to laughable. | bmel | |
02/11/2020 09:34 | IXI i will Top Up at any dips....great product and service. IXI will grow rapidly but short term may be taken over... | halfpenny | |
28/10/2020 12:21 | Updated based on potential takeover. IXI could double as US companies seek value. IXI technology is a game changer. Like HZD i said was great have just gone up 100%. IXI the next big opportunity at these levels... | halfpenny | |
28/10/2020 12:13 | Wow now looking great opportunity. Only way is up up up | halfpenny | |
28/10/2020 11:49 | Halfwit says: "IXI was hit by Covid" IXI Trading statement Monday 19 Oct says: "We have responded robustly to the challenges of the COVID-19 pandemic, continuing our track record of strong growth." Which the numbers evidence. Guess that makes you a liar? | bmel | |
28/10/2020 10:33 | IXI the question is now HOW HIGH!!! INCREASE can be due TO a correction here and can RISE very very quickly. Do you feel lucky, I DO!!! See HZD bought out | halfpenny | |
28/10/2020 09:55 | Alter Ego Read his posting history. One of those who believe in 'MMs playing games with prices', probably other fairy tales too. 'Transparent' is a compliment lol. | bmel | |
28/10/2020 09:37 | got your short lined up eh? So transparent. | alter ego | |
28/10/2020 09:30 | IXI see STATS... see Chart as Higher Highs are proving positive. Follow the chart for guidance... | halfpenny | |
28/10/2020 09:29 | IXI updated prospect due to HZD seen as opportunity | halfpenny | |
28/10/2020 09:22 | IXI ...changed my view ....can go up very quickly!! Worth a punt... | halfpenny | |
08/10/2020 16:18 | One suspects a break out to ATH would be something of a coiled spring. | hpcg | |
08/10/2020 11:52 | At all time highs and at top of a wedge. | mad foetus |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions